文献速递前列腺癌

低危家族性前列腺癌患者术后升级或分期升高的风险

Risk of Postoperative Up Staging or Upgrading among Men with Low Risk Familial Prostate Cancer.
PubMed 文献 · J Urol · 2020-01-31

该研究基于全国人群队列,纳入6854例低危前列腺癌根治性前列腺切除术患者,其中1739例(25%)有一级亲属前列腺癌史,289例(4%)有一级亲属高侵袭性或致死性前列腺癌史。与无家族史者相比,有高风险或致死性前列腺癌家族史者术后分期升高和病理升级的比值比分别为1.06(95%CI 0.76-1.47)和1.17(95%CI 0.91-1.50),无统计学关联。

要点

  • 低危前列腺癌患者中,一级亲属前列腺癌史与术后分期升高或病理升级无显著关联。
  • 有高风险或致死性前列腺癌家族史者,术后分期升高OR为1.06(95%CI 0.76-1.47)。
  • 有高风险或致死性前列腺癌家族史者,术后病理升级OR为1.17(95%CI 0.91-1.50)。

核心结论

  • 家族性前列腺癌史与低危患者根治性前列腺切除术后分期升高或病理升级无关联。

研究设计与样本

  • 全国人群为基础的队列研究,纳入6854例低危前列腺癌且接受根治性前列腺切除术的男性。

主要发现

  • 1739例(25%)有一级亲属前列腺癌史,289例(4%)有一级亲属高侵袭性或致死性前列腺癌史。
  • 有高风险或致死性前列腺癌家族史者术后分期升高OR为1.06(95%CI 0.76-1.47)。
  • 有高风险或致死性前列腺癌家族史者术后病理升级OR为1.17(95%CI 0.91-1.50)。

临床怎么用

  • 低危前列腺癌患者决策时,家族史不应作为预测术后分期升高或病理升级的独立因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated whether men with biopsy verified, low grade cancer and a family history of lethal or advanced prostate cancer are at particularly high risk for harboring undetected high grade disease. MATERIALS AND METHODS: Upgrading and up staging of prostate cancer are common after prostatectomy. In a nationwide population based cohort we identified 6,854 men with low risk prostate cancer who underwent radical prostatectomy. Among these men 1,739 (25%) had a history of prostate cancer in a first-degree relative and 289 (4%) had a first-degree relative with lethal or advanced prostate cancer. RESULTS: Compared to men with no familial occurrence of prostate cancer, the odds ratio for the risk of up staging among men with a familial occurrence of high risk or lethal prostate cancer was 1.06 (95% CI 0.76-1.47). The corresponding odds ratio for upgrading was 1.17 (0.91-1.50). CONCLUSIONS: We found no association between family history of prostate cancer and up staging or upgrading after radical prostatectomy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Jansson F, Folkvaljon F, Stattin P, et al. Risk of Postoperative Up Staging or Upgrading among Men with Low Risk Familial Prostate Cancer. J Urol. 2020. PMID: 32003613. doi:10.1097/JU.0000000000000793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。